FDA Chronic kidney disease

Ozempic receives FDA nod for treating chronic kidney disease

FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic kidney disease,

CNBC on MSN · 2d

FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use

Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves a gradual loss of kidney function.

The Baltimore Sun · 9h

FDA approves Ozempic to help reduce risk of worsening chronic kidney disease

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of

Contract Pharma15h

FDA Approves Ozempic in Chronic Kidney Disease

The approval is based on results from the Phase III FLOW trial demonstrating Ozempic reduced the risk of severe kidney outcomes by 24% compared to placebo, including kidney failure, reduction in ...

Q&A: How a scientist helped ban a chemical connected to Parkinson's disease

The U.S. will ban nearly all uses of the common industrial cleaning agent, trichloroethylene (TCE), this year—more than 50 ...

Inverse9h

Ozempic And Other GLP-1s Show Promise With 42 Conditions — But There Are Still Big Risks

Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...

Renal & Urology News14h

KDIGO Issues New ADPKD Guideline

KDIGO guideline is the first specifically addressing autosomal dominant polycystic kidney disease (ADPKD) and focuses on some unique aspects of management.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results